Introduction
Non-alcoholic fatty liver disease (NAFLD) is now the most common form of liver disease worldwide. It represents a spectrum of disorders affecting the liver that is rapidly becoming not only a significant indication for liver transplantation and cause of liver-related morbidity and mortality, but also a significant cause of extrahepatic morbidity and mortality. NAFLD is defined as evidence of hepatic steatosis (> 5%) by imaging or histology and the absence of other causes of steatosis such as significant alcohol consumption, medications, or hereditary disorders [1] . It exists along a spectrum of disease from a state of steatosis to advanced disease states: steatosis with fibrosis or non-alcoholic steatohepatitis (NASH) with or without fibrosis, and finally, cirrhosis. Steatosis, in the absence of fibrosis, represents the most benign state within the spectrum of disease and carries little to no risk of progression. However, steatosis confers an increased risk of diabetes mellitus and cardiovascular disease and recent data suggest that steatosis with fibrosis, in the absence of NASH, is associated with risk of progressive liver disease.
NAFLD prevalence varies by ethnicity with the highest rates seen in Hispanics [3] . In contrast to other causes of chronic liver disease such as viral hepatitis infections and alcoholic liver disease, which have remained stable in the last decades, the prevalence of NAFLD has steadily increased [4] . Given that the prevalence of many of these risk factors is expected to increase, especially obesity, it is likely that the prevalence of NAFLD will continue to rise and contribute greatly to the burden of chronic liver disease worldwide.
NAFLD is associated with a significant burden to the affected individual and the healthcare system. Affected individuals often complain of fatigue and abdominal pain which can limit physical function, affect job stability, and reduce quality of life [5] . The number of patients utilizing healthcare resources for NAFLD and the many associated comorbidities continue to rise. Younossi et al. studied the economic burden of NAFLD in the USA and estimated the annual burden associated with all incident and prevalent NAFLD cases to be $103 billion with a 10-year economic burden of up to about $1 trillion after adjusting for annual growth in prevalence of obesity [6] .
Pathophysiology
Non-alcoholic fatty liver disease is often thought of as the hepatic manifestation of the metabolic syndrome. The pathophysiology of NAFLD is a complex interaction between genetic, environmental, and gut microbial modulators resulting in the excessive accumulation of triglycerides in hepatocytes. Accumulation of hepatic triglycerides results from an imbalance between uptake from dietary intake, plasma free fatty acids (FFA) flux from adipose tissue, and hepatic de novo lipogenesis (DNL) and export in the form of very low density lipoprotein (VLDL), FFA oxidation, and phospholipid synthesis [7] .
Dietary intake, plasma FFA flux from adipose tissue, and DNL contribute 15, 59, and 26%, respectively, to hepatic lipid uptake in NAFLD [8] . Multiple studies in mice have shown increased hepatic steatosis in mice fed high-fructose and hightrans fat diets [9, 10] . In addition, when these diets are withdrawn, steatosis reverses [11] . High saturated fat and cholesterol diets also lead to steatosis [12, 13] . A similar diet high in unsaturated fat and cholesterol and low in polyunsaturated fat has been demonstrated in human subjects with NASH and is associated with increased insulin resistance and other features of the metabolic syndrome [14] .
Circulating plasma FFAs are largely derived from lipolysis from adipose tissue. Hepatocyte FFA uptake is largely a function of plasma FFA concentration and transport proteins. NAFLD patients are often obese with hyperlipidemia and have upregulation of fatty acid transport proteins, resulting in a significant contribution of plasma FFA flux from adipose tissue to hepatic steatosis [8, 15] .
De novo lipogenesis (DNL), regulated by insulin and glucose levels, is also increased in NAFLD. Hepatic insulin resistance and hyperglycemia result in increased DNL. Hyperglycemia activates the transcription factor, carbohydrate responsive element-binding protein (ChREBP), which in turn activates liver pyruvate kinase resulting in increased fatty acid production [16] . Hyperinsulinemia upregulates another transcription factor, sterol regulatory element-bind protein-1c (SREBP-1c), which induces expression of lipogenesis genes resulting in increased DNL [17, 18] .
Changes in the gut microbiome have also been associated with the metabolic syndrome and NAFLD. When fed a highfat diet, most C57BL/6J mice develop steatosis and other features of the metabolic syndrome (responders), while some mice did not (non-responders). When the fecal microbiota of those responder mice was transplanted into non-responders, they developed similar features of the metabolic syndrome and upregulation of transcription factors ChREBP and SREBP-1c [19] . The exact mechanism through which the gut microbiome exerts its effects on hepatic steatosis is not clear. Increased intestinal permeability resulting in liver inflammation and impaired insulin signaling is suggested by some studies associating small intestinal bacterial overgrowth (SIBO) in NAFLD, but results have been inconsistent [20] [21] [22] . Gut bacteria may also play a role in increasing free fatty acid absorption and efflux to the liver. Germ-free mice transplanted with the microbiome from conventional mice have increased monosaccharide absorption, increased DNL, and suppressed Fasting-induced adipocyte factor (Fiaf), an intestinally produced circulating lipoprotein lipase inhibitor, resulting in increased triglyceride storage [23, 24] . Colonic bacteria are also involved in directly increased fatty acid production through the fermentation of non-digestible carbohydrates into short-chain fatty acids (SCFA) [25] . In a human study, subjects with metabolic syndrome who received fecal transplant from lean donors had a non-significant lowering of SCFA levels compared to those who received autologous transplants as well as a significant increase in butyrateproducing bacteria [26] .
Increasingly, genetic variations that affect lipid metabolism are being increasingly recognized as playing a crucial role in the development of NAFLD and the discrepancy seen between rates of the metabolic syndrome and prevalence of NAFLD among different ethnicities [27] . Several genomewide association analyses have shown that a missense mutation in the PNPLA3 gene, with highest prevalence in Hispanics, is associated with insulin resistance and increased risk of NAFLD [28•, 29] . Another genome-wide association analysis showed that a variant in the gene TM6SF2 confers increased risk of NAFLD and is associated with increased hepatic triglycerides and decreased VLDL production [30•] .
Variants in the apolipoprotein C gene are also associated with NAFLD in a population of Asian Indian men resulting in increased fasting and postprandial hypertriglyceridemia and resultant hepatic steatosis [31] .
Identification of Patients with NAFLD
The majority of patients with NAFLD are asymptomatic or have non-specific symptoms (fatigue, nausea, abdominal pain) and have normal and mild abnormalities on physical exam (hepatomegaly, obese). Most patients are diagnosed with NAFLD via incidental finding of steatosis on imaging or incidentally noted elevated liver enzymes which prompt imaging. In addition, patients with NAFLD risk factors including obesity, the metabolic syndrome, and diabetes are sometimes screened by clinicians for NAFLD, although data for the efficacy of this is lacking [32] .
In the care of patients with NAFLD, it is imperative to identify those patients with advanced disease from those patients with steatosis. Ultrasound has a sensitivity of 93% when there is more than 33% of steatosis, but sensitivity is less than 30% in those with < 33% steatosis [33] . CT has a sensitivity of about 82% in detecting moderate to severe steatosis and is based on attenuation (Hounsfield units). Given that many patients with NAFLD may have a mild degree of steatosis, the sensitivity of CT for mild steatosis is lower than that for moderate to severe [34] . The low sensitivity coupled with exposure to radiation makes CT a less desirable method for evaluation of NAFLD. MRI (including MR spectroscopy) is able to detect steatosis with high accuracy with sensitivity for mild hepatic steatosis of > 5% of about 80-90% but it is expensive and therefore not cost-effective [34] . Both CT and MRI do not differentiate steatosis from steatohepatitis. Despite these limitations, ultrasound is a reasonable first test for a patient with a high likelihood of NAFLD. If an ultrasound is negative and a high pre-test probability remains, CT or MRI should be performed.
Serum liver chemistry tests also do not reliably predict the presence of steatosis or any other entity in the NAFLD spectrum. Serum ALT has been looked at in many studies and it is concluded that steatosis (or any other form of NAFLD) can exist with normal ALT levels and that the histology in patients with normal ALT levels does not differ from those with higher ALT levels [35] .
The gold standard for the diagnosis of NAFLD, differentiating between steatosis and NASH, and staging fibrosis is liver biopsy. Since fibrosis is associated with worse outcomes and overall mortality, selection of patients with liver biopsy is based on a prediction of likelihood of significant fibrosis. The NAFLD fibrosis score (NFS), calculated by using body mass index, presence of diabetes/impaired fasting glucose, platelet count, albumin, and ALT and AST levels, is a model that helps identify patients with more advanced disease who may benefit from a liver biopsy [36•] . More recently, imaging modalities such as vibration-controlled transient elastography (fibroscan) or elastography with acoustic radiation and magnetic resonance elastography (MRE) have been used to quantify the degree of liver fibrosis. These modalities are not widely available and can be costly. The controlled attenuation parameter (evaluated with transient elastography) is a new non-invasive technique that is being used in select centers to measure the degree of steatosis but its use remains to be validated. Its modalities can accurately determine the extremes of fibrosis (stages 0-1 vs. 2-4) but lack the ability to differentiate reliably between stages.
Morbidity and Mortality Mortality
While NAFLD is an important cause of morbidity and mortality worldwide, the implications of steatosis alone are less clear. Several studies have found increased mortality in NASH subjects compared to the general population, but steatosis, itself, has not been associated with increased mortality [37, 38] . In a retrospective Swedish study, mortality over a 28-year period of biopsy-proven NAFLD patients was compared to the general Swedish population. All-comer NAFLD patients had 69% increased risk of mortality compared to the general population; however, when divided into NASH and steatosis subgroups, mortality among steatosis patients was no longer statistically significant [37] . Kim et al. used data from the National Health and Nutrition Examination Survey (NHANES) to extract non-invasive markers of fibrosis among ultrasonographically identified NAFLD patients. They found no increased mortality among all-comer NAFLD identified by ultrasonography compared to NHANES controls, but statistically significant increased mortality among the subgroups was identified by non-invasive fibrosis markers to have advanced fibrosis [38] .
In contrast with the above studies, a recent longitudinal study in patients with NAFLD indicated increased mortality even in non-NASH patients in the presence of fibrosis. In this study, fibrosis stage was independently associated with longterm overall mortality, liver transplantation, and liver-related events. In the same study, patients that had steatosis with fibrosis had similar outcomes to patients with NASH with fibrosis [39••] .
Morbidity
Increasing evidence suggests that NAFLD independently contributes to cardiovascular disease, type 2 diabetes mellitus, and renal disease [40] . Several mechanisms have been proposed including hepatic inflammation, hepatic dysfunction, or steatosis. This suggests that steatosis is not as benign as currently known to be and that perhaps steatosis has metabolic effects leading to increased morbidity.
Liver Disease
Steatosis and steatosis with non-specific inflammation in the absence of fibrosis carry a low risk of progression to end-stage liver disease. Liver-related mortality is not elevated among those with steatosis compared to the general population. In a cohort of 40 patients with steatosis followed over a median of 11 years, none developed clinical signs of fibrosis or cirrhosis [41] . Similarly, in a Danish study of 417 patients with biopsyproven steatosis (170 NAFLD, 247 alcoholic), only 2 (1.2%) NAFL patients clinically developed cirrhosis over a median of 20.4 years of follow-up compared to 54 (22%) alcoholic patients (median of 21.0 years of follow-up) [42] . Histologic data, however, suggests progression of liver disease even among steatosis or steatosis with non-specific inflammation patients. A retrospective review of 70 patients with biopsyproven NAFLD showed, of 25 patients with steatosis, 16 (64%) developed NASH and 6 (24%) bridging fibrosis over a median of 3.7 years of follow-up. Disease progression was associated with increased weight and incidence of diabetes [43] . Wong et al. showed in a prospective paired-biopsy study including 12 with steatosis that 3 (23%) developed NASH on repeat biopsy after 3 years [44] . A systematic review of paired-biopsy studies found an annual fibrosis progression rate of 0.07 for patients with steatosis compared with 0.14 for NASH indicating progression of one stage of fibrosis every 14.3 years for NAFL patients and every 7.1 years for NASH patients [45] . This discrepancy between clinical and histologic studies may indicate that progression of liver disease in steatosis patients is reduced and individuals may succumb to comorbid conditions such as cardiovascular disease prior to developing advanced liver disease.
Angulo et al., however, showed that in the presence of fibrosis, even steatosis carries an increased risk of mortality, liver transplantation, and liver-related events [39••] . Patients with advanced disease are at higher risk for progression to cirrhosis than those with just steatosis [46] , and often times, identification of these patients goes unnoticed because of a lack of diagnostic tests for advanced disease.
Hepatocellular Carcinoma
The incidence of hepatocellular carcinoma (HCC) is significantly increased in patients with obesity and diabetes [47] . In addition, the incidence of HCC is increased among patients with NAFLD, especially NASH. Studies of populations with cryptogenic cirrhosis and HCC revealed that HCC likely developed in the setting of unrecognized NASH [48, 49] . HCC can develop in NASH in the presence or absence of fibrosis, but data on HCC development in steatosis is lacking. While the incidence of hepatocellular carcinoma (HCC) is significantly increased in patients with obesity and diabetes [47] , the role of steatosis in this risk is unknown.
Cardiovascular Disease
NAFLD is an independent risk factor for cardiovascular disease [50, 51] and has been associated with increased risk of ischemic heart disease, heart failure, valvular disease, and arrhythmias [52] . Evidence for increased cardiovascular risk in steatosis patients independent of NASH is limited. The degree to which steatosis increases one's cardiovascular risk is not as well defined as the risk across the NAFLD spectrum and needs further research.
Some studies note an association between hepatic steatosis and coronary artery defects. Mellinger et al. noted a significant association between hepatic steatosis, as identified by CT, and coronary calcifications using CT [53] with an odds ratio of 1.2. Another study by Osawa et al. noted that a significantly higher percentage of subjects with hepatic steatosis (measured by liver to spleen fat ratio) have a higher number of CTdetected coronary plaques than subjects without steatosis [54] . These studies were performed independent of CVD risk factors and suggest that steatosis itself is associated with coronary artery defects, though they cannot fully isolate the contribution of non-NASH NAFLD.
A case-control study examined 150 biopsy-proven NAFLD patients and quantified liver fat using MRI-proton density fat fraction (MRI-PDFF), dividing patients into above the median (15.4% fat fraction) and below the median groups. They found an association between fat quantity and cardiovascular risk factors (abdominal obesity, low HDL, high triglycerides, and high fasting glucose) independent of biopsyproven NASH, but did not specifically look at cardiovascular outcomes [55] . Another study looked at echocardiographic speckle-tracking findings of left ventricular global longitudinal strain (LV-GLS) in NAFLD patients compared to healthy controls. This study found significantly lower LV-GLS in steatosis, borderline NASH, and NASH patients compared to healthy controls, but no difference between the NAFLD subgroups [56] .
Musso et al. looked at 40 non-obese, normolipidemic, nondiabetic patients with biopsy-proven NAFLD compared to 40 healthy controls. Patients were administered oral fat load and glucose tolerance tests and lipid profiles, adipose insulin resistance, and adipokines were measured postprandially. Steatosis and NASH patients demonstrated similar fasting values; however, NASH patients demonstrated more atherogenic lipoprotein profiles compared to simple steatosis patients suggesting a dysfunctional response to fat ingestion in NASH predisposing to increased cardiovascular risk compared to steatosis [57] .
Type 2 Diabetes
There have been multiple studies showing that intrahepatic lipid content is independently associated with decreased insulin sensitivity, and that the presence of steatosis in the liver increases the risk of developing type 2 diabetes mellitus. Also important is the fact that a decrease in the hepatic fatty content leads to a reduction in the risk of developing type 2 diabetes mellitus [58] [59] [60] . This suggests that steatosis and diabetes mellitus are closely interrelated in terms of cause and effect. However, these have been mostly small studies in specific obese adult populations and need further validation and the majority of these studies have not differentiated between NASH and non-NASH NAFLD.
One systematic review found 6 studies using ultrasounddiagnosed NAFLD and 12 studies using liver function test (LFT) abnormalities to diagnose NAFLD. Among the ultrasound studies, 4/6 found NAFLD predicted type 2 diabetes mellitus (T2DM) independent of age, obesity, family history, and BMI (all studies were independent of age). All studies using LFT abnormalities to diagnose NAFLD predicted T2DM independent of age and BMI [61] . Steatosis and diabetes share similar risk factors and pathogenesis and it is not clear from current studies whether increased risk of T2DM in NAFLD stems from something intrinsic to NAFLD itself or is related to NASH and associated inflammation.
The study by Musso et al. in which 40 biopsy-proven NAFLD patients were administered oral fat load and glucose tolerance tests also looked at postprandial adipose and hepatic insulin resistance. Similar to their cardiovascular findings, NASH was associated with impaired B cell function and increased adipose and hepatic insulin resistance compared to steatosis [57] .
Colon Cancer
The second leading cause of death in NAFLD patients after cardiovascular disease is extrahepatic malignancy [37] . NAFLD has been implicated in increased risk of gastric, esophageal, pancreatic, renal, melanoma, breast, and prostate cancer [62] , though the evidence for a role in these cancers is not well proven and often conflicting. The association between colorectal cancer and NAFLD, however, is much more established, though it does not appear that this risk extends to steatosis. In one cross-sectional study of 199 biopsy-proven NAFLD patients, NAFLD patients had an increased risk of colorectal adenomas and advanced neoplasms compared to healthy controls (34.7 vs. 21.5% and 18.6 vs. 5.5%, respectively). NASH patients had higher risk of adenomas and advanced neoplasms compared to steatosis patients (51.0 vs.
25.6% and 34.7 vs. 14.0%, respectively) and the difference between steatosis patients and healthy controls was not statistically significant [63] . While data is limited, it does not appear that steatosis in and of itself confers additional risk of colorectal cancer compared to the general population.
Chronic Kidney Disease
Numerous studies have noted a correlation between chronic kidney disease (CKD) and NAFLD [64] . A small number of these studies have sought to break down the influence of steatosis compared to NASH. In one study of 87 biopsy-proven NAFLD patients, 14 were found to have microalbuminuria. While there was no statistically significant difference in the prevalence of microalbuminuria between NASH and non-NASH patients, there were a small number of steatosis patients in the study (1 with microalbuminuria and 4 without). In addition, fibrosis scores were significantly higher in NAFLD patients with microalbuminuria than those without [65] . A cross-sectional study of 174 biopsy-proven NAFLD patients showed significantly increased rates of CKD in NASH patients compared to non-NASH patients. Out of 92 NASH and 87 non-NASH patients, 24 (14%) were found to have CKD with 19 (21%) having NASH and 5 (6%) non-NASH [66] .
Management Lifestyle Interventions
The most effective treatment for NAFLD is lifestyle interventions aimed at weight loss. Weight loss (either through dietary or exercise intervention) of about 3-5% has been associated with a reduction in the amount of steatosis [1] . In a metaanalysis by Musso et al. where four randomized studies were evaluated, more than 7% weight loss was needed to show statistically significant improvement in the NAFLD activity score for patients with NASH but there were no improvements in fibrosis [57] . In other recent studies, ≥ 10% weight loss was needed to make improvements in biopsy-proven NASH fibrosis [67, 68] with one study citing steatosis improvement in 100% of patients, steatohepatitis resolution in 90% of patients, and fibrosis regression in 45% of patients with at least 10% total body weight loss. In the same study, a weight loss of at least 5% had some benefit with steatosis improvement in about 35% of patients. Although the optimal diet has not been agreed upon, for improvement of steatosis, data supports that a diet low in sugars, carbohydrates, and saturated fats and high in fiber and healthy fats (monounsaturated, omega 3) with the goal of gradual weight loss of about 2 lbs per week improves disease [69] . In a study by Kistler et al., 54% of 813 adult patients with NAFLD reported an inactive activity level [70] . In the same study, NAFLD patients who achieved a MET of 6 or more for 75 min a week had lower odds of having NASH than those who did not. Another study showed that moderate to vigorous physical activity (> 250 min weekly) significantly reduced NAFLD pathophysiology parameters such as levels of hepatic steatosis by fibroscan and abdominal visceral adiposity by MRI [71] . Current recommendations for treatment of all types of NAFLD (steatosis, steatosis with fibrosis, NASH, and NASH with fibrosis) advocate for lifestyle interventions in the form of both diet and exercise as they are thought to have a greater effect together than either one alone [72] .
Pharmacologic Interventions
Pharmacologic treatment of NAFLD is targeted to those patients with advanced disease at risk for progression such as steatosis with fibrosis, NASH, and NASH with fibrosis. Pharmacological treatment such as vitamin E and pioglitazone has shown improvement in steatosis and inflammation in patients with NASH without DM and in patients with NASH with DM, respectively [73] . Omega-3 fatty acids have shown improvement in radiographic steatosis and pentoxifylline has shown improvement in steatosis and ballooning in patients with NASH but these treatments need further validation [74, 75] . Metformin, ursodiol, and orlistat have shown no benefits [32] . Ursodeoxycholic acid (UDCA), HMG Co-A-reductase inhibitors, and ezetemibe have also been studied and so far have not achieved beneficial results or have yielded conflicting results [76] .
Surgical Interventions
Bariatric surgery improves all stages of NAFLD (and might even cure NAFLD by reducing steatosis significantly to less than < 5%) not only through its effect on weight but also through an improvement in insulin resistance and in the proinflammatory state caused by obesity [77] .
In summary, therapy for all NAFLD should focus on weight reduction through diet and exercise. Pharmacological and surgical therapies do not apply for patients with steatosis or non-NASH without fibrosis.
Conclusion
The available literature on NAFLD clearly demonstrates that it is a worldwide health problem. The significance of non-NASH NAFLD (steatosis) within the spectrum of NAFLD remains to be defined. The pathophysiology of steatosis and its progression to NASH is not currently well known, though research into the microbiome and genetic underpinnings of the disease is promising. The available data suggests a relatively benign course of steatosis compared to NASH in terms of overall mortality and increased risk of extrahepatic complications of NAFLD. However, it does appear that steatosis progresses to NASH at least histologically, but the clinical significance of this remains unclear and how and whom to follow remains ill-defined. Finally, treatment options for NAFLD across the spectrum remain limited, but more so for steatosis. Given the relatively benign course of steatosis, treatment of comorbidities and lifestyle interventions aimed at diet and exercise are currently recommended. Further research is needed to identify which patients with steatosis may progress so that they can be safely and effectively be chosen for therapy.
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